Skip to content

Clinical study of prostatic artery embolization for benign prostatic hyperplasia

Clinical study of prostatic artery embolization for benign prostatic hyperplasia

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2100049993
Enrollment
Unknown
Registered
2021-08-15
Start date
2021-08-01
Completion date
Unknown
Last updated
2022-04-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

BPH

Interventions

Control Group:bleomycin
test group:CalliSpheres

Sponsors

Department of Interventional Radiology, Chinese PLA General Hospital
Lead Sponsor

Eligibility

Sex/Gender
Male
Age
50 Years to 90 Years

Inclusion criteria

Inclusion criteria: 1. Aged over 50 years old; 2. Drug treatment for more than 6 months ineffective; 3. Moderate-to-severe lower urinary tract obstruction symptoms due to benign prostatic hyperplasia: Quality of life score (QoL) >3 points, International Prostate Symptom Score (IPSS) >18 points, maximum urinary flow rate (Qmax) 50 mL; 5. Prostate-specific antigen (PSA) >4 ng/mL or prostate MRI prompts malignant tumors, prostate biopsy is required to exclude malignant lesions; 6. Those who are unsuitable or unwilling to undergo surgical treatment due to combined underlying diseases.

Exclusion criteria

Exclusion criteria: 1. Prostate malignant tumor; 2. Allergic to iodine-containing contrast agents; 3. Those who have received PAE treatment in the past; 4. Previous surgical resection of the prostate; 5. Combined with severe urinary tract infection (active stage); 6. Neurogenic bladder or detrusor dysfunction; 7. Urethral stricture; 8. Chronic renal failure; 9. Severe abnormal coagulation function; 10. Those with mental disorders who cannot cooperate; 11. Huge bladder stones (>5 cm); 12. Those who are not expected to complete postoperative follow-up; 13. Those who have metal implants (such as: steel plates, etc.) in the body cannot perform MRI scans.

Design outcomes

Primary

MeasureTime frame
prostate volume;

Countries

China

Contacts

Public ContactYuan Bing

Department of Interventional Radiology, Chinese PLA General Hospital

978354482@qq.com+86 15910800782

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026